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ABSTRACT 28 
There is an urgent need for an effective vaccine against human disease caused by B. 29 
pseudomallei, and although a wide range of candidates have been tested in mice none 30 
provide high level protection. We considered this might reflect the inability of these vaccine 31 
candidates to protect against chronic disease. Using Q-RT PCR we have identified 6 genes 32 
which are expressed in bacteria colonising spleens and lungs of chronically infected mice. 33 
Three of the genes (BPSL1897, BPSL3369 and BPSL2287) have been expressed in E. coli 34 
and the encoded proteins purified. We have also included BPSL2765, a protein known to 35 
induce immune responses associated with a reduced incidence of chronic/recurrent disease 36 
in humans. Immunisation of mice with a combination of these antigens resulted in the 37 
induction of antibody responses against all of the proteins. Compared with mice immunised 38 
with capsular polysaccharide or LolC protein, mice immunised with the combination of 39 
chronic stage antigens showed enhanced protection against experimental disease in mice. 40 
 41 
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1. Introduction 57 
Burkholderia pseudomallei is the etiological agent of melioidosis, a serious and often fatal 58 
disease of humans and a wide variety of animals [1]. The disease is an important medical 59 
problem in many tropical regions of the world. For example, in North-East Thailand, 60 
melioidosis is the third most common cause of death from infectious diseases, exceeded 61 
only by HIV and tuberculosis [2]. In Darwin, Northern Australia, melioidosis is the most 62 
common cause of fatal community-acquired septicemic pneumonia [3]. Melioidosis is difficult 63 
to treat as B. pseudomallei is resistant to many antibiotics [4].  The bacterium is susceptible 64 
to some newer β-lactam antibiotics including ceftazidime [5, 6] but a protracted course of 65 
treatment (typically 20 weeks) is routinely required [7]. Chronic disease is common and 66 
disease relapse has been reported [8, 9] . 67 
 68 
Against this background, there may be an opportunity to use vaccines for the control of 69 
naturally occurring disease. Recent work has shown that a vaccine would be a cost-effective 70 
intervention in Thailand if used in high-risk populations such as diabetics [10]. However, at 71 
present there is no available human vaccine, though a wide range of candidates including 72 
live attenuated mutants, killed cells, protein or polysaccharide sub-units and naked DNA 73 
vaccines have been tested in mice (for recent reviews see [11-13]). All of these vaccines are 74 
able to induce some protective immunity, protecting against the acute form of the disease. 75 
However, all of the candidates fail to provide long-term control of disease of which 76 
persistent, chronic melioidosis is a feature.  77 
 78 
B. pseudomallei differs from many other pathogens, yet is similar to Mycobacterium 79 
tuberculosis, in its capacity for intracellular survival for many years. Chronic melioidosis is 80 
often misdiagnosed as tuberculosis and the two diseases have common histological features 81 
such as the presence of multinucleated giant cells and granulomas, suggesting that 82 
melioidosis and tuberculosis have shared immunological mechanisms. Like melioidosis, it is 83 
difficult to devise vaccines that provide sterile immunity against tuberculosis. However, one 84 
promising approach is to devise tuberculosis sub-unit vaccines which include antigens 85 
expressed during the chronic or latent phase of disease [14-16]. These vaccines have been 86 
shown to be effective in animal models of disease and are currently in human clinical trials 87 
[17].  88 
 89 
Recently, the B. pseudomallei transcriptional response to a range of in vitro conditions 90 
reflecting the diversity of niches occupied by the bacterium was reported [18]. Evaluation of 91 
the transcriptional response of B. pseudomallei in conditions mimicking the environment 92 
inside the granuloma, including hypoxia and nutrient starvation, has provided clues to the 93 
repertoire of antigens expressed by the pathogen as it adapts to long-term persistence in the 94 
host. Our hypothesis is that it is possible to prime the host immune system to target B. 95 
pseudomallei during the chronic stage of melioidosis by selecting vaccine antigens 96 
expressed by the bacterium in the chronic phase of infection. In this study we have 97 
identified, constructed and evaluated chronic stage vaccine candidates in the murine model 98 
of infection. Our results indicate that, in a murine model of disease, the degree of protection 99 
afforded by immunisation with chronic stage vaccine antigens is greater than the protection 100 
afforded by two of the leading sub-unit candidates (CPS and LolC). 101 
 102 
 103 
2. Materials and Methods 104 
 105 
2.1 Bacterial strains 106 
B. pseudomallei strains 576 and K96243 were used in this study. Both are clinical isolates of 107 
B. pseudomallei from cases of melioidosis in Thailand [19]. The intraperitoneal (i.p) median 108 
lethal doses of these strains are reported to be 80 and 262 colony forming units (CFU) 109 
respectively [19]. Bacteria were cultured in Luria-Bertani (LB) medium at 37°C.  110 
 111 
2.2 Identification of chronic stage antigens  112 
B. pseudomallei transcriptional profiles from in vitro conditions thought to reflect the 113 
environment inside a granuloma were obtained [18]. Transcriptome data was referenced to 114 
the transcriptome profile of B. pseudomallei grown in LB broth at 37°C.  Transcriptional 115 
responses from B. pseudomallei grown in low pH, peroxide, low oxygen and low nutrient 116 
(water) were interfaced and evaluated, and genes that were upregulated in at least three of 117 
the four granuloma mimicking conditions were selected. The annotation and cellular location 118 
of the protein products of selected genes using PSORTb [20] were evaluated.  119 
  120 
2.3 Chronically infected mouse tissues 121 
Chronic infection studies were performed in accordance with the guidelines of the Animals 122 
(Scientific Procedures) Act of 1986 and were approved by the local ethical review 123 
committee at the London School of Hygiene and Tropical Medicine. Female C57BL/6 mice 124 
(6-8 week-old; Harlan Laboratories, Bicester, Oxon, UK) were used throughout the chronic 125 
infection studies. For each infection, aliquots were thawed from frozen bacteria stocks and 126 
diluted in pyrogen-free saline (PFS). Prior to intranasal (i.n) infection, mice were 127 
anesthetized intraperitoneally (i.p) with ketamine (50 mg/kg; Ketaset; Fort Dodge Animal, 128 
Iowa, USA) and xylazine (10 mg/kg; Rompum; Bayer, Leverkusen, Germany) diluted in 129 
PFS. Infection was performed by administering a total volume of 50 µl i.n. containing 100 130 
CFU of B. pseudomallei strain 576. Infection dose was confirmed as described elsewhere 131 
[21]. Control uninfected mice received 50 µl i.n. of PFS. At day 65, 95 and 102 p.i. mice 132 
were killed and lungs and spleens aseptically removed into 3ml of cold Trizol®Reagent 133 
(Invitrogen, CA, USA). Organs were homogenized using a Polytron homogenizer and 134 
samples were stored at -80oC until further processing. 135 
 136 
2.4 Isolation of mRNA from infected mouse tissue 137 
Total RNA was extracted from the infected lung and spleen homogenates in Trizol®Reagent 138 
described above according to the manufacturer’s recommendations. In brief, cell debris was 139 
removed by centrifugation at 12,000xg for 10 mins. Supernatants (1 ml each) were 140 
transferred to fresh tubes and 0.2 ml chloroform was added to initiate phase separation. 141 
The samples were centrifuged for 15 min at 12,000xg at 4°C, and the aqueous phase was 142 
transferred to fresh tubes. Total RNA was precipitated by adding 0.5ml isopropanol and 143 
incubating the samples over-night at -20°C. The RNA was pelleted by centrifugation for 45 144 
min at 13,000 rpm at 4°C; the supernatant was discarded, and the pellet washed with 75% 145 
ethanol in DEPC-water. The RNA pellet was air dried for 5 mins at room temperature and 146 
re-suspended in 50l nuclease-free water. Contaminating DNA was removed by on-column 147 
DNase I digest and RNA cleanup using the RNeasy kit (Qiagen) according to the 148 
manufacturer’s recommendations. In brief, 350μl RLT buffer supplemented with 10μl/ml ß-149 
mercaptoethanol and 250μl absolute ethanol was added to each RNA sample, before 150 
loading onto RNeasy spin columns. After brief centrifugation, 350l RW1 buffer was added 151 
and columns re-centrifuged. 10μl DNase I stock solution (27 Kunitz units) mixed with 70 μl 152 
Buffer RDD (both component of the RNase-free DNase kit, Qiagen) were added to the 153 
columns, which were incubated at room temperature for 30 mins. The columns were 154 
washed once with 350μl RW1 buffer and twice with 500l RPE buffer. Total RNA was 155 
eluted in 2x40l nuclease-free and checked for DNA contamination by PCR. RNA from 6 156 
mice in each experimental group was pooled before reverse transcription PCR analysis. 157 
 158 
2.5 Quantitative reverse transcription PCR 159 
Reverse transcription (RT) and PCR were performed in a single reaction using Quantitect 160 
SYBR Green RT PCR kit (Qiagen) according to the manufacturers' instructions. For 161 
template, total RNA from the lungs and spleens of six chronically infected mice collected at 162 
65 days, 95 days and 102 days post infection was pooled into separate lung and spleen 163 
template samples. Three PCRs were carried out for each chronic gene of interest using total 164 
RNA isolated from lungs and, separately, spleen. One control was performed for each 165 
chronic gene of interest using total RNA isolated from bacteria in lungs and spleen as 166 
template but without the RT step. B. pseudomallei housekeeping genes BPSL2188 (aceA) 167 
and BPSL3159 (gltB) were used as internal controls for expression profiling. Both BPSL2188 168 
and BPSL3159 were selected as controls as neither of the genes was found to be 169 
differentially regulated in vivo in mice compared to broth culture (data not presented). In a 170 
reaction volume of 50μl, 25μl of 2 X QuantiTect SYBR Green RT-PCR master mix, 0.5 μM of 171 
forward and reverse primers, 0.5μl QuantiTect RT mix, <500ng template RNA, RNase-free 172 
water was added to make the reaction volume to 50 μl.  PCR reaction conditions were; 50°C 173 
for 30 minutes for reverse transcription, followed by a PCR initial activation step of 95°C for 174 
15 minutes. Four step cycling of 94°C for 15 seconds (denaturation), 50°C for 30 seconds 175 
(annealing), 72°C for 30 seconds (extension) and 40°C for 15 seconds (40 cycles). 176 
Reactions were performed using a Stratagene Mx3005P Q-PCR system. Ct values were 177 
calculated for all samples. Relative expression levels were calculated using 2-ΔΔct analysis.  178 
 179 
2.6 Antigen production 180 
Genes encoding for BPSL1897 (residues 40 to 155), BPSL3369 (residues 1 to 506) and 181 
BPSL2287 (residues 1 to 107) were purchased as codon-optimised synthetic genes 182 
(GenScript). To facilitate subsequent cloning by digestion and ligation into pGEX4T-1 (Life 183 
Technologies), BamH1 and EcoR1 restriction sites were added at the 5’ and 3’ ends of the 184 
genes, respectively. BPSL1897, BPSL3369 and BPSL2287 were expressed as N-terminal 185 
glutathione-S-transferase (GST) fusion proteins in BL21 Star™ (DE3) cells (Life 186 
Technologies) in Luria Bertani Broth (BPSL3369 and BPSL2287) or Terrific Broth 187 
(BPSL1897), inducing with 0.5 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) at 20°C 188 
overnight.  189 
 190 
Bacterial cells from a 0.5 L culture were harvested and lysed in PBS using a cell disruption 191 
system at 25mPa (Constant Systems Limited). Following centrifugation at 18,000 rpm and 192 
addition of 50 g/l deoxyribonucleases (Sigma-Aldrich) and 10 mM magnesium chloride, 193 
the soluble fraction was loaded onto a 5 ml GSTrap FF column (BPSL2287) or 5 ml 194 
Glutathione Sepharose 4B resin (GE healthcare) in a gravity-flow setup (BPSL3369), pre-195 
equilibrated with PBS containing 10 % glycerol and 5 mM dithiothreitol (DTT). A final wash 196 
was carried out with PBS to remove DTT and glycerol prior to cleavage with 20U 197 
(BPSL3369) or 40U (BPSL2287) thrombin (Sigma-Aldrich). Tag cleavage was carried out in 198 
PBS, incubating overnight at 20C (with gentle rotation for batch purifications). Thrombin 199 
was removed from the cleaved protein solutions using a 1 ml HiTrap Benzamidine FF 200 
column (GE Healthcare), pre-equilibrated in PBS containing 1M NaCl. Proteins were 201 
exchanged into PBS using a PD10 desalting column (GE Healthcare) and concentrated to 202 
1mg/ml using Amicon Ultra-15 Centrifugal Filter Units (Millipore) with an appropriate MW cut-203 
off. Recombinant BPSL2765 was produced as a N-terminal histidine-tagged protein as 204 
previously described (Gourlay et al, 2013). Residues 47 to 243 of BPSL2277 (LolC-N) were 205 
cloned into pET28a and expressed with an N-terminal histidine tag in Rosetta (DE3) pLysS 206 
cells in LB, inducing with 0.5mM IPTG at 20°C overnight. Bacterial cells from a 0.5 L culture 207 
were harvested and mechanically lysed in PBS, and fractionated as described above. 208 
Following DNAse treatment, the supernatant was loaded onto a 5 ml Bio-Scale Mini Profinia 209 
IMAC cartridge (Bio-rad) and exchanged into PBS using a 50ml Mini-Scale Bio-Gel P6 210 
Desalting cartridge using the Profinia Protein Purification System, according to standard Bio-211 
rad protocols. The protein was purified on a HiLoad Superdex 75 (16/60) gel filtration 212 
column, pre-equilibrated in PBS (flow rate of 1ml/min), using an AKTA Protein Purification 213 
System (GE Healthcare). Proteins were analysed by SDS-PAGE on a 12% Bis-Tris 214 
NuPAGE pre-cast gel (Life technologies) in NuPAGE MES running buffer, or a 12% Bolt Bis-215 
Tris Plus pre-cast gel (Life technologies) in Bolt MOPS running buffer (BPSL1897). 216 
 217 
Manno-heptopyranose capsular polysaccharide (CPS) was prepared from an O-antigen 218 
deficient mutant strain B. thailandensis E555::wbiI (pKnock-KmR).This strain was generated 219 
through disruption of the O-antigen synthesis cluster in B. thailandensis E555 [22] by 220 
insertional inactivation of the wbiI gene (gene BTH_I1483 in B. thailandensis E264) using the 221 
pKnock-Km suicide vector [23]. Briefly, an internal fragment from the wbiI gene in B. 222 
thailandensis E555 was amplified by PCR using primers 306 (5’- 223 
CTGCAGTCTATCGGGCGACGAAGGAG-3’) and 307 (5’- 224 
CTGCAGGCCTTGTCGGTCGAGATCAG-3’), inserted into pCR®-blunt II-TOPO® and cloned 225 
into E. coli TOP10 cells. Following sequence verification, the insert was released by 226 
digestion with KpnI and XbaI and purified by gel extraction using a MinElute Gel Extraction 227 
kit (Qiagen). This was ligated into similarly prepared pKnock-Km vector and cloned into E. 228 
coli S17-1 λ-pir. The resulting pKnock-Km-wbiI vector was transferred into B. thailandensis 229 
E555 by conjugation and recombinants were selected by supplementing growth media with 230 
kanamycin and gentamicin. Insertion into wbiI was confirmed by Southern hybridization and 231 
loss of O-antigen synthesis was confirmed by Western hybridization following SDS PAGE 232 
using the O-antigen specific monoclonal CC6 [24]. Continued synthesis of the manno-233 
heptose capsule was confirmed by Western hybridization using the capsule-specific 234 
monoclonal 4VIH12 [25]. Capsular polysaccharide was isolated from this strain using a 235 
modified hot aqueous-phenol procedure of Burtnick et al. [26].   236 
 237 
2.7 Protection study 238 
Protection studies were carried out according to the requirements of the UK Animal 239 
(Scientific Procedures) Act 1986 under project licence PPL 30/2623. This project licence was 240 
approved following an ethical review by Dstl’s Animal Welfare and Ethical Review Body. 241 
Protection studies were performed using female BALB/c mice (BALB/c; Charles River UK) 242 
implanted with a sub-cutaneous Pico transponder (Uno BV, Netherlands). Mice were 6 - 8 243 
weeks of age and weighed 16 - 20 grams on arrival. Mice were randomly allocated into 244 
cages of five with environmental enrichment. Mice were under a 12 hour light/dark cycle (at 245 
19 to 23°C and 45 to 65% relative humidity. There was free access to food (Labdiet certified 246 
rodent diet 5002 and Labdiet EUrodent 22% diet 5LF5; International Product Supplies) and 247 
water throughout the study. Mice were housed in a conventional animal unit during 248 
immunisations in rooms supplied with rough filtered air giving 20 to 25 air changes per hour. 249 
Mice were checked at least twice daily following challenge and clinical signs for each mouse 250 
were scored. Throughout this study humane end-points were used to minimise suffering, 251 
with culls performed via cervical dislocation at the end-point. 252 
 253 
Mice (n=10 per immunogen) were immunised via the i.p. route with immunogen formulated 254 
in SAS adjuvant (monophosphoryl lipid A from Salmonella minnesota (25µg per mouse per 255 
dose) and synthetic trehalose dicorynomycolate (25µg per mouse per dose) as an oil-in-256 
water emulsion of 2% squalene and 0.2% Tween® 80; Sigma). Chronic proteins were 257 
delivered as a pool (BPSL2765, BPSL3369, BPSL2287 and BPSL1897, 5μg of each protein 258 
per mouse per dose). Purified CPS (10µg per mouse per dose) was delivered in combination 259 
with the chronic antigens where appropriate. Immunisations were performed on days 0, 14 260 
and 28 and mice were challenged five weeks after the final immunisation with 7.46 x 104 261 
CFU of B. pseudomallei K96243 (100 X LD50) via the i.p. route. 262 
 263 
2.8 IgG1 and IgG2A ELISA 264 
Serum was recovered from the tail vein of each mouse two weeks after the final 265 
immunization and pooled by cage (to give n=2 per vaccine). Antibody responses directed 266 
against the various protein antigens were assessed by ELISA essentially as previously 267 
described [27] using 5µg/ml of each protein to coat ELISA wells. A reading of twice 268 
background or above was considered positive and the titer was determined to be the 269 
reciprocal of the final positive dilution. 270 
 271 
3. Statistical analysis 272 
Survival data was analysed in the program GraphPad PRISM v6.0 using a log rank (Mantel-273 
Cox) test. Significance was assessed at the 95% confidence level. 274 
 275 
4. Results 276 
 277 
4.1 Identification of chronic stage antigens 278 
We first compared the gene expression profile of B. pseudomallei grown in granuloma 279 
mimicking conditions. Nine putative chronic infection stage B. pseudomallei genes that were 280 
upregulated in at least three of four in vitro conditions; low oxygen, nutrient deprivation, low 281 
pH and peroxide were identified: BPSL0296, BPSL2287, BPSL2289, BPSL3312, 282 
BPSS0369, BPSL1899, BPSL3369, BPSL3247 and BPSL1897. The nine genes represented 283 
different classes of genes, including hypothetical proteins with membrane or extracellular 284 
locations (Table 2).  285 
 286 
4.2 Quantitative reverse transcriptase PCR using total RNA lungs and spleens of chronically 287 
infected mice. 288 
We next tested whether any of the putative chronic infection stage B. pseudomallei genes 289 
were expressed during chronic disease. Total RNA from individual mice which had been 290 
challenged with bacteria and developed chronic disease [28] was reverse transcribed and 291 
amplified and gene-specific mRNA quantified using real time PCR. The use of multiple 292 
internal controls, aceA and gltB, allowed quantification of transcripts from each of the 293 
putative chronic stage genes in pooled lung and spleen samples from mice. B. pseudomallei 294 
putative chronic genes BPSL1897, BPSL3369, BPSL0296, BPSL3247, BPSL2287 and 295 
BPSL1899 were transcribed at higher levels than one or both housekeeping genes aceA 296 
and gltB in both lungs and spleens of chronically infected mice (Table 3). B. pseudomallei 297 
genes BPSL3312, BPSL2289 and BPSS0369 were transcribed at a lower level than 298 
housekeeping genes in lungs and spleens of chronically infected mice. Therefore, of the nine 299 
genes identified from in vitro transcriptome analysis, six, BPSL0296, BPSL1897, BPSL1899, 300 
BPSL2287, BPSL3247 and BPSL3369, were found to be expressed at levels higher than 301 
housekeeping genes by B. pseudomallei during chronic infection. These genes were 302 
therefore selected for over-expression of the encoded proteins. 303 
 304 
4.3 Over-expression and purification of proteins  305 
Of the 6 genes we identified that were highly expressed during chronic infection, we were 306 
able to overexpress and purify three of the encoded proteins (BPSL1897, BPSL2287 and 307 
BPSL3369). Two of the proteins (BPSL0296 and BPSL3247) were insoluble when 308 
expressed in E. coli and we could not detect expression of BPSL1899. tested BPSL1897, 309 
BPSL2287 and BPSL3369 were expressed as N-terminal GST-tagged fusion proteins, and 310 
purified as described in the Materials and Methods section. Yields ranged from 2 to 5 mg per 311 
litre of bacterial culture (Table 4). Following removal of the GST-tag, BPSL3369 migrated 312 
with a MW in line with the theoretical value of 55.6 kDa (Fig. 1). There were diverse bands 313 
visible for BPSL2287 at approx. 12 kDa, 14 kDa, 26 kDa, 28 kDa, and a faint band at 40 kDa 314 
(Fig. 1). As BPSL2287 contains three cysteine residues in the conserved CXnCGCG motif 315 
shared by HesB family members it is likely that the 12 kDa and 14 kDa bands correspond to 316 
diversely compacted forms of the protein monomer, whereas the 26 kDa and 28 kDa bands 317 
are likely to represent variably reduced dimeric forms of the protein. The highest band (40 318 
kDa) is a likely tetrameric form. Such observations are in agreement with its structural 319 
homolog (71% sequence identity), an iron-sulfur [2Fe-2S] cluster assembly protein (IscA) 320 
from E. coli (PDB entry 1S98) that exists in both dimeric and tetrameric forms in solution 321 
[29]. As it was not possible to remove the GST tag (25 kDa) from BPSL1897 (11.9 kDa), the 322 
tagged form of the protein produced a band at approx. 35 kDa.  323 
 324 
We also selected BPSL2765 for testing as a chronic stage antigen. Suwannasaen et al., [30] 325 
previously showed that antibodies against BPSL2765 were found at 10-fold-higher levels in 326 
patients who had only one episode of melioidosis, in comparison with patients who had 327 
suffered recurrent episodes. This finding suggests that responses against BPSL2765 328 
provide protection against chronic / recurrent disease. BPSL2765 was produced as a 329 
histidine-tagged protein as previously reported [31] with a yield of 23 mg/L culture and was 330 
judged to be >95% pure (Table 2). LolC was purified (approx. 20 mg protein/L culture; > 90% 331 
pure) as a C-terminal His-tag, as described in the Materials and Methods section, and 332 
migrated with a MW of 26k Da, in agreement with its theoretical MW of 26.4 kDa (Fig. 1). 333 
Protein purity for all antigens was judged by SDS-PAGE and ranged from 90-95 % (Table 4). 334 
 335 
4.4 ELISA 336 
Mice were immunised with a combination of BPSL2765, BPSL3369, BPSL2287 and 337 
BPSL1897 as described above. The immunised mice were tail-bled two weeks after the final 338 
boost and levels of serum antibodies were assessed using an ELISA (Table 5). The 339 
polarisation of the immune response was assessed through analysis of levels of antigen-340 
specific IgG1 and IgG2a; the relative proportions of these sub-classes reflect the bias of an 341 
immune response in the mouse. All of the mice immunised with adjuvant only failed to 342 
produce detectable IgG1 or IgG2a to the chronic stage antigens. In mice receiving the 343 
vaccines containing chronic stage proteins, strong levels of both IgG1 and IgG2a were 344 
produced to proteins BPSL3369 and BPSL2287 whereas IgG2A but not IgG1 was produced 345 
in response to proteins BPSL1897 and BPSL2765. The inclusion of CPS or LolC in the 346 
formulation of chronic stage antigens did not modify the antibody responses to these chronic 347 
stage proteins (data not shown) 348 
 349 
4.5 Protection studies 350 
To determine whether B. pseudomallei BPSL2765, BPSL3369, BPSL2287 and BPSL1897 351 
are protective antigens, groups of BALB/c mice were immunised as described above and 352 
challenged a month later with 7.46 x 104 CFU of B. pseudomallei K96243 via the intra-353 
peritoneal route. Other groups of mice were immunised with either CPS or LolC, or a 354 
combination of chronic antigens and CPS or LolC, since CPS and LolC are the most 355 
protective vaccine candidates identified to date [32]. The challenged mice were observed 356 
until 49 days post infection (Fig 2).  357 
 358 
The mean time to death (mttd) of the group of control mice dosed with PBS was 2.5 days. All 359 
of the immunised mice showed significant protection (p<0.01) compared to these control 360 
mice. The immunised mice showed similar levels of protection until day 21, but after that 361 
time groups immunised with preparations containing chronic stage antigens showed greater 362 
protection than the groups immunised with either CPS or LolC (p<0.01). The mttd of mice 363 
dosed with LolC or CPS was 28.5 days and the mttd of mice dosed with chronic stage 364 
antigens was 42 days. The mttd of groups of mice immunised with a combination of LolC or 365 
CPS and the chronic stage antigens was 45 and 41.5 days respectively, and there was no 366 
significant increase in protection of these mice compared to mice immunised with chronic 367 
stage antigens alone.  368 
 369 
 370 
5. Discussion 371 
A wide range of melioidosis vaccine candidates have been tested in mice over the past 372 
decade. None of these candidates consistently provide sterile immunity against disease, but 373 
some extend the time to death of mice challenged with B. pseudomallei. It is uncertain 374 
whether it will be possible to develop vaccines that provide robust and sterile immunity, and 375 
we report here the potential for chronic stage vaccine antigens to contribute to protection.  376 
 377 
Recently, tuberculosis vaccines that combine virulence factors expressed during the early 378 
stages of disease with latency-associated antigens have been shown to provide enhanced 379 
protection against disease, and to control re-activation [14, 15]. These vaccines (ID93 and 380 
H56) are currently being trialled in humans [17]. Chronic disease is an important feature of 381 
melioidosis, but the mechanisms that underlie persistence and the immune responses that 382 
develop during chronic infection are poorly characterised. Multinucleated giant cells and 383 
granulomas are histological features of both chronic melioidosis and chronic tuberculosis in 384 
humans and experimental animals suggesting that, as in tuberculosis, intracellular survival is 385 
key to the persistent and chronic phase of melioidosis. Devising vaccines against pathogens 386 
that can enter a latent, subclinical state capable of causing chronic or recurrent disease is a 387 
major challenge.  388 
 389 
Two partially protective sub-unit antigens that we have identified to date are LolC [33] and 390 
CPS [32]. Immunisation with B. pseudomallei CPS extends the time to death but does not 391 
provide sterile immunity, instead the acute disease is shifted to the chronic form. Immunity 392 
directed against CPS is expected to be due to the presence of antibodies. This is consistent 393 
with the protective capacity of CPS specific monoclonal and polyclonal antibodies when 394 
administered passively to animals [32]. A similar pattern of protection is seen after 395 
immunisation with LolC, a protein component of a lipoprotein transport system. The 396 
immunisation of mice results in the appearance of a more chronic form of disease following 397 
challenge [33]. Therefore, to go beyond the level of protection afforded by CPS or LolC 398 
alone, different vaccine components may be required.  399 
 400 
In this study we aimed to improve on the protection elicited by immunisation with CPS or 401 
LolC alone through identification of antigens that are upregulated during chronic or recurrent 402 
melioidosis. We have identified a subset of B. pseudomallei genes that are expressed during 403 
chronic melioidosis in mice. The level of expression of these genes was measured relative to 404 
two housekeeping genes (aceA and gltB), in RNA isolated from spleen or lung tissues taken 405 
from chronically infected mice. We selected these housekeeping genes because we had 406 
previously shown that they were not differentially regulated in bacteria taken from acutely 407 
infected mice, compared to bacteria grown in broth cultures [18]. Using RNA isolated from 408 
chronically infected spleens, the relative levels of expression of the chronic stage antigen 409 
genes were similar when compared to the level of expression either aceA or gltB. However, 410 
in lung tissues the ratio compared to aceA was approximately 10-fold higher than the ratio 411 
compared to gltB (Table 3). This finding suggests that aceA or gltB are differentially 412 
expressed in different tissues of chronically infected mice. 413 
 414 
BPSL1897 is a hypothetical protein located in the cytoplasmic membrane and contains a 415 
Tad-E domain that is often found in pilus assembly protein components. BPSL3369 encodes 416 
an acetaldehyde dehydrogenase and has a cytoplasmic cellular location.  BPSL0296 is a 417 
small, hypothetical protein of unknown cellular location. BPSL3247 encodes a putative 418 
lipoprotein and has multiple predicted cell localisations. BPSL2287 is an iron cluster 419 
assembly protein and BPSL1899 encodes a putative fimbrial assembly like protein. Putative 420 
chronic stage vaccine candidates BPSL2765, BPSL3369, BPSL2287 and BPSL1897 were 421 
selected for protection studies in mice. In addition, BPSL2765, an outer membrane protein 422 
(OmpA), was included in the vaccine antigen pool as previous studies have shown that the 423 
antibody response to this protein is correlated with reduced incidence of recurrent disease in 424 
humans [30].  425 
 426 
Mice immunised with the pool of chronic stage antigens developed antibody responses to all 427 
of the proteins. The response to BPSL1897 and BPSL2765 demonstrated a bias towards a 428 
Th1 type response, evidenced by high levels of IgG2a whilst the response to BPSL3369 and 429 
BPSL2287 indicated both Th1 and Th2 type responses, evidenced by elevated levels of both 430 
IgG2a and IgG1. 431 
 432 
Immunisation with the combination of chronic stage antigens provided protection against 433 
experimental melioidosis. Our results indicate that by including chronic stage antigens 434 
protection is enhanced compared to two of the leading sub-unit candidates (CPS and LolC) 435 
identified to date. Further work should determine whether one or more of the proteins are 436 
responsible for the enhanced protection we have seen. However, even with the 437 
combinations of antigens we tested we were unable to demonstrate sterile immunity against 438 
the challenge dose we tested. Therefore, it is clear that the antigens we have identified, even 439 
in combination, are not sufficient to provide an effective sub-unit vaccine. Against this 440 
background, it would be valuable to identify and test additional chronic stage proteins as 441 
protective antigens. 442 
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Table 1. Primers used for Q-RT PCR analysis of gene expression 460 
Primer name Primer sequence 
BPSL3312 F GAATATCTCGCGTTTCTCGG 
BPSL3312 R TCTGTGCTTCGTTGATCTCG 
BPSL2289 F CAATTTTGTCGAAGGCGAAT 
BPSL2289 R TAGTCGACTTCCTGCTCCGT 
BPSL1897 F TCGACGAACTACACGTGCTC 
BPSL1897 R ATGATGTTGGTCGGGTTGAT 
BPSL2287F AAAGCCTTGCGTACATCGAC 
BPSL2287R GTCCTTCACGTTCGGATTGT 
BPSL3369F ATCTGAACATCGAATTCCCG 
BPSL3369R ACGTTGTCGAAATACTCGCC  
BPSL3247F AACGCCCTCGTCTATCACAC 
BPSL3247R TGCTGTTGAAGTAGCCGTTG 
BPSL0296F TACGGTAGGTGAAATTGCGG 
BPSL0296R CGTCGTCCTTCTTTTTCTCG 
BPSL1899F GATGCATCGCTTCTTCAAGG 
BPSL1899R ATAAGACCGGCGATCAACC 
BPSS0369F ATCGTCTGCGTGTGCAAGT 
BPSS0369R AACTGGAGTTCTTCGAACGTG 
BPS gltB F CGCACCATGACATCTATTCG 
BPS gltB R ACCGGATTGACGTTCTTCAG 
BPS aceA F CTCTGGACGCTCATCAACAA 
BPS aceA R CCGATACAGCTGAAGAAGCG 
 461 
  462 
Table 2. Genes encoding putative chronic stage antigens in B. pseudomallei  463 
 464 
Target  Predicted function Predicted cellular localisationa 
BPSL0296  hypothetical protein unknown 
BPSS0369  putative bacterioferritin ferredoxin 
protein 
unknown 
BPSL1897  hypothetical contains a Tad-E 
domain 
cytoplasmic membrane 
BPSL1899  putative fimbrial assembly like 
protein 
unknown 
BPSL2287  iron cluster assembly protein cytoplasmic 
BPSL2289  cysteine desulfurase cytoplasmic 
BPSL3247  lipoprotein  multiple predicted localisations 
BPSL3312  putative glycosyltransferase Cytoplasmic 
BPSL3369  acetaldehyde dehydrogenase  Cytoplasmic 
 465 
a predicted using PSORTb version 3.0.2  466 
 467 
Table 3. Relative (compared to aceA or gltB) levels of expression of genes encoding 468 
putative chronic stage antigens in B. pseudomallei pooled mRNA isolated from the lung or 469 
spleens of 6 chronically infected mice.   470 
 471 
Target  lung (aceA)  lung (gltB)  spleen (aceA)  spleen (gltB)  
BPSL0296  2.5  0.3  10.6  13.6  
BPSS0369  2.1e-3  2.5e-4  0.75  0.96  
BPSL1897  17.1  2.1  1.17  1.5 
BPSL1899  5  0.44  1.4  1.8  
BPSL2287  2.6  0.3  2.78  3.58  
BPSL2289  0.29  0.036  0.01  0.016  
BPSL3247  2.6  0.3  6.6  8.5  
BPSL3312  4.16  0.5  0.08  0.11  
BPSL3369  12.1  1.5  4.4  5.65  
 472 
 473 
 474 
 475 
  476 
Fig. 1.  SDS-PAGE analysis of purified chronic antigens. Plasmids carrying chronic antigen 477 
genes were transformed into BL21(DE3)Star cells or Rosetta (DE3) pLysS cells (N-LolC) 478 
and protein expression was carried out, as described in the Materials and Methods section. 479 
Purified bands of N-LolC, BPSL2765 and BPSL3369 are indicated by arrows 1 to 3, 480 
respectively.  The diverse oligomeric forms of BPSL2287 are indicated by arrows 4 (4M1 481 
and 4M2 = monomeric forms 1 and 2; 4D1 and 4D2 = dimeric forms 1 and 2, and 4T1 = 482 
tetrameric form), and the band corresponding to GST-BPSL1897 is indicated by arrow 5. 483 
Molecular weight markers (Genespin S.r.l.) are indicated on the left in both panels in kDa. 484 
 485 
486 
  487 
 488 
 489 
Fig 2. Survival of mice (n=10 per immunogen) which had been immunised on days 0, 14 and 490 
28 and challenged with 7.46 x 104 CFU of B. pseudomallei K96243 (100 X LD50) via the i.p. 491 
route. 492 
 493 
 494 
  495 
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